Nat Med: CAR T cells targeting both CD19 and CD22 to treat relapsed or refractory B-cell malignancies: Phase I trial 

The chimeric antigen receptor-modified T cells and natural killer (NK) cells targeting CD19 (CAR19) have impressive anti-tumor effects and promote relapsed or chemotherapy-refractory (relapsed/refractory) B cell malignancies The transformation of the treatment model

Clinical factors such as pre-CAR disease burden and serum lactate dehydrogenase (LDH) are related to the response to CAR19 therapy

Some reports also indicate that effective CAR T cell response requires high target antigen expression density

CD22 is an adhesion molecule that binds to sialic acid, which is mainly limited to B cell lines and is expressed on most B line malignant tumors

Recently, in order to prevent the recurrence of CD19- or CD19lo disease, researchers tested one in a phase I clinical trial (NCT03233854) for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and LBCL adults Bispecific CAR for CD19 and/or CD22 (CD19-22.

CD19-22.

Therefore, the results of this study further imply that antigen loss is the main cause of CAR T cell resistance , highlighting the challenge that engineered multispecific CAR T cells have the same potency on different targets, and confirming that the production of cytokines is CAR An important quality indicator of T cell potency

Original source:

Jay Y.